Assenagon Asset Management
ENTA icon

Assenagon Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Assenagon Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,877
Closed -$723K – 1141
2025
Q4 		$723K Sell
45,877
-8,380
-15% -$106K ﹤0.01% 1006
2025
Q3 		$649K Sell
54,257
-52,123
-49% -$417K ﹤0.01% 1007
2025
Q2 		$804K Sell
106,380
-6,292
-6% -$37.8K ﹤0.01% 953
2025
Q1 		$622K Sell
112,672
-80,184
-42% -$495K ﹤0.01% 982
2024
Q4 		$1.11M Buy
192,856
+49,050
+34% +$470K ﹤0.01% 1084
2024
Q3 		$1.49M Sell
143,806
-282,755
-66% -$3.7M ﹤0.01% 1037
2024
Q2 		$5.53M Sell
426,561
-157,097
-27% -$2.12M 0.01% 608
2024
Q1 		$10.2M Hold
583,658
– – 0.02% 422
2023
Q4 		$5.49M Sell
583,658
-47,968
-8% -$447K 0.01% 607
2023
Q3 		$7.06M Buy
631,626
+543,111
+614% +$8.75M 0.02% 478
2023
Q2 		$1.89M Sell
88,515
-29,842
-25% -$880K 0.01% 795
2023
Q1 		$4.79M Buy
118,357
+65,946
+126% +$3.15M 0.02% 592
2022
Q4 		$2.44M Buy
52,411
+29,353
+127% +$1.34M 0.01% 744
2022
Q3 		$1.2M Sell
23,058
-114,208
-83% -$6.67M ﹤0.01% 888
2022
Q2 		$6.49M Buy
137,266
+2,080
+2% +$113K 0.02% 480
2022
Q1 		$9.62M Buy
135,186
+23,703
+21% +$1.54M 0.03% 376
2021
Q4 		$8.34M Buy
111,483
+16,334
+17% +$1.28M 0.02% 376
2021
Q3 		$5.41M Buy
95,149
+78,792
+482% +$3.89M 0.02% 412
2021
Q2 		$720K Buy
+16,357
New +$801K ﹤0.01% 966
2020
Q4 		– Sell
-136,204
Closed -$6.24M – 1081
2020
Q3 		$6.24M Buy
136,204
+87,381
+179% +$4.23M 0.04% 280
2020
Q2 		$2.45M Buy
+48,823
New +$2.53M 0.02% 542

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Assenagon Asset Management's ENTA Position: Q1 2026 in Review

Assenagon Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 45,877 shares — an estimated $723K sold.

Assenagon Asset Management first reported a position in ENTA in Q2 2020 and held it in 21 quarters. The position peaked at $10.2M in Q1 2024. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Assenagon Asset Management reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Assenagon Asset Management sold 45,877 Enanta Pharmaceuticals shares in Q1 2026, an estimated $723K.
  • Assenagon Asset Management first reported a position in Enanta Pharmaceuticals in Q2 2020 and held it in 21 quarters.
  • Assenagon Asset Management's Enanta Pharmaceuticals position peaked at $10.2M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Assenagon Asset Management's 13F filing for Q1 2026, filed 20 Apr 2026.